blog.fdazilla.com
Description: Blog Fdazilla. Trends & Analysis Reports on key industry issues by our GxP Experts Read Here Conference Spotlight Conference updates from...
  • Google PR 3
    Trustworthiness Good
  • Avg. Daily Visitors N/A
    Child Safety Excellent
  • Avg. Daily Pageviews N/A
    Privacy Good

Blog - Govzilla

Blog.fdazilla.com: get to the top rated Blog Fdazilla pages and content popular with USA-based Blog.fdazilla.com users or check the following digest to find out more. Blog.fdazilla.com is a malware-free website without age restrictions, so you can safely browse it. It seems that Blog Fdazilla team are just starting to conquer the social media and they have already achieved a promising result — 7 user activities so far (Google+ dominates with around 40% of all user reactions). Blog.fdazilla.com is hosted with CloudFlare, Inc. in United States. Blog Fdazilla traffic is not yet estimated by Alexa.
Visit blog.fdazilla.com

Domain info

Location: United States
Registrant: Redacted for Privacy (Privacy service provided by Withheld for Privacy ehf)
Hosted by: CloudFlare, Inc.
Registrar: NameCheap, Inc.
Subnetworks: 104.27.154.37, 104.27.155.37, 172.67.215.184

Social Media Activities

  • Facebook likes: -
  • Twitter mentions: 2
  • Google pluses: 3
  • LinkedIn mentions: 2
  • Pinterest pins: -
  • StumbleUpon views: -

Web Safety

  • This website is malware-free.
  • Status ok
See Google Transparency Report

Sites associated with the same registrant

Whois

Expand

Blog.fdazilla.com popular pages to visit

Govzilla BLOG – Search Less. Know More. The essential tool for compliance and regulatory professionals. Barbara W. Unger September 4, 2019 Software is used extensively in both the drug and device industry for computerized systems in manufacture and testing activities along with being us...
3 Theories Why FDA Inspections are Down 25% | FDAZILLA BLOG   Based on our latest data, we're seeing a major downturn in FDA inspections this year. Possibly 25%. Check out the chart above. As you can see, the
3 FDA 483 Stories in the Last 3 Weeks – Gilead, Alexion, and Novartis | FDAZILLA BLOG Now I know why we've been getting more calls/emails from financial institutions and hedge funds inquiring about FDA 483s - more and more investors are being

Other websites we recently analyzed